Premium
COVID ‐19, neuroleptic malignant syndrome and psychosis
Author(s) -
Grant Calum,
Keay Jonathan A,
Shah Bardhan Jung,
Adeeko Babatunde
Publication year - 2021
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.713
Subject(s) - neuroleptic malignant syndrome , clozapine , psychosis , covid-19 , medicine , case presentation , presentation (obstetrics) , symptomatic treatment , pediatrics , psychology , psychiatry , schizophrenia (object oriented programming) , surgery , virology , disease , infectious disease (medical specialty) , outbreak
Neuroleptic malignant syndrome (NMS) can be a severe condition requiring emergency treatment. Misdiagnosis or delay in treatment can prove fatal. An unusual presentation of NMS is outlined in a patient being restarted on clozapine following a mild COVID‐19 infection. A discussion on NMS explores its pathogenicity and the various ways it can present clinically, which further illustrates the atypical features of this case.